###begin article-title 0
###xml 90 95 <span type="species:ncbi:9606">human</span>
An additive interaction between the NFkappaB and estrogen receptor signalling pathways in human endometrial epithelial cells
###end article-title 0
###begin title 1
BACKGROUND
###end title 1
###begin p 2
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 302 307 <span type="species:ncbi:9606">human</span>
Human embryo implantation is regulated by estradiol (E2), progesterone and locally produced mediators including interleukin-1beta (IL-1beta). Interactions between the estrogen receptor (ER) and NF kappa B (NFkappaB) signalling pathways have been reported in other systems but have not been detailed in human endometrium.
###end p 2
###begin title 3
METHODS AND RESULTS
###end title 3
###begin p 4
###xml 424 428 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 464 468 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
Real-time PCR showed that mRNA for the p65 and p105 NFkappaB subunits is maximally expressed in endometrium from the putative implantation window. Both subunits are localized in the endometrial epithelium throughout the menstrual cycle. Reporter assays for estrogen response element (ERE) activity were used to examine functional interactions between ER and NFkappaB in telomerase immortalized endometrial epithelial cells (TERT-EEC). E2 and IL-1beta treatment of TERT-EECs enhances ERE activity by a NFkappaB and ER dependent mechanism; this effect could be mediated by ERalpha or ERbeta. E2 and IL-1beta also positively interact to increase endogenous gene expression of prostaglandin E synthase and c-myc. This is a gene-dependent action as there is no additive effect on cyclin D1 or progesterone receptor expression.
###end p 4
###begin title 5
CONCLUSION
###end title 5
###begin p 6
In summary, we have established that NFkappaB signalling proteins are expressed in normal endometrium and report that IL-1beta can enhance the actions of E2 in a cell line derived from healthy endometrium. This mechanism may allow IL-1beta, possibly from the developing embryo, to modulate the function of the endometrial epithelium to promote successful implantation, for example by regulating prostaglandin production. Aberrations in the interaction between the ER and NFkappaB signalling pathways may have a negative impact on implantation contributing to pathologies such as early pregnancy loss and infertility.
###end p 6
###begin title 7
Introduction
###end title 7
###begin p 8
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 121 141 121 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C31">Jabbour <italic>et al</italic>., 2006</xref>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 143 166 143 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C56">van Mourik <italic>et al</italic>., 2009</xref>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 588 611 588 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C56">van Mourik <italic>et al</italic>., 2009</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human endometrium is a dynamic tissue that undergoes cycles of proliferation, differentiation, breakdown and repair (Jabbour et al., 2006; van Mourik et al., 2009). The development of the endometrium in preparation for implantation of the fertilized conceptus is under the control of the sex steroid hormones, estradiol and progesterone. Implantation occurs during the mid-late secretory phase of the menstrual cycle (the 'implantation window') and is characterized as an inflammatory event associated with increased expression of inflammatory mediators and immune cell infiltration (van Mourik et al., 2009).
###end p 8
###begin p 9
###xml 171 176 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 161 183 154 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C13">Critchley <italic>et al</italic>., 2001</xref>
###xml 185 189 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C14">2002</xref>
###xml 191 218 184 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C12">Critchley and Saunders 2009</xref>
###xml 452 457 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 445 464 434 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C38">Lessey <italic>et al</italic>., 1988</xref>
###xml 476 481 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 466 488 455 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C13">Critchley <italic>et al</italic>., 2001</xref>
###xml 594 599 580 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 584 606 570 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C28">Henderson <italic>et al</italic>., 2003</xref>
###xml 722 727 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 712 734 698 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C14">Critchley <italic>et al</italic>., 2002</xref>
###xml 827 832 810 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 817 839 800 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C14">Critchley <italic>et al</italic>., 2002</xref>
###xml 862 867 845 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 854 874 837 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C7">Bombail <italic>et al</italic>., 2008</xref>
The actions of estrogens on the endometrium are mediated by estrogen receptors (ER)alpha and ERbeta both of which are expressed in epithelial and stromal cells (Critchley et al., 2001, 2002; Critchley and Saunders 2009). Immunoexpression of ERalpha varies during the normal cycle with intense staining in epithelial and stromal cells during the proliferative phase but a marked reduction in the functional layer during the late secretory phase (Lessey et al., 1988; Critchley et al., 2001). In contrast, ERbeta alone is expressed in both endothelial and uterine natural killer cells (Henderson et al., 2003) and appears similar in epithelial and stromal cells during both the proliferative and secretory phases (Critchley et al., 2002). As a result ERbeta appears to be the predominant isoform in both the glandular (Critchley et al., 2002) and surface (Bombail et al., 2008) epithelium during the implantation window.
###end p 9
###begin p 10
###xml 530 535 514 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 524 542 508 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C37">Laird <italic>et al</italic>., 2000</xref>
###xml 549 554 533 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 544 561 528 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C45">Page <italic>et al</italic>., 2002</xref>
###xml 638 643 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 633 650 609 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C45">Page <italic>et al</italic>., 2002</xref>
Inflammatory events including immune cell infiltration can be mediated via activation of NF kappa B (NFkappaB)-dependent gene transcription. NFkappaB is a dimeric transcription factor consisting of homo- or hetero-dimeric complexes of the Rel family of proteins; in the inactive state the complex is sequestered in the cytoplasm by a family of endogenous inhibitors, called IkappaBs. Previous studies have reported that expression of the NFkappaB subunits, p65 (Rel A) and p50, are increased during the mid secretory phase (Laird et al., 2000; Page et al., 2002) although expression of IkappaBalpha is reported to fall at this time (Page et al., 2002). These semi-quantitative immunohistochemical studies would be consistent with a role for NFkappaB activation during the implantation window. However, this has not been confirmed using quantitative analysis.
###end p 10
###begin p 11
###xml 157 162 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 150 169 146 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C6">Biswas <italic>et al</italic>., 2005</xref>
###xml 171 184 167 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C26">Harnish, 2006</xref>
###xml 390 403 386 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C26">Harnish, 2006</xref>
###xml 589 597 581 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 607 612 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 599 619 591 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C27">Harnish <italic>et al</italic>., 2000</xref>
###xml 629 634 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 621 641 613 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C20">Feldman <italic>et al</italic>., 2007</xref>
###xml 655 660 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 643 667 635 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C47">Quaedackers <italic>et al</italic>., 2007</xref>
###xml 673 680 665 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 688 693 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 682 700 674 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C18">Evans <italic>et al</italic>., 2001</xref>
###xml 773 778 761 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 761 785 749 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C47">Quaedackers <italic>et al</italic>., 2007</xref>
###xml 879 884 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 869 891 849 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C42">Nakshatri <italic>et al</italic>., 1997</xref>
###xml 897 902 877 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 893 909 873 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C53">Sun <italic>et al</italic>., 1998</xref>
###xml 1074 1079 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1082 1086 1058 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C3">2008</xref>
###xml 1471 1476 1436 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1464 1483 1429 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C21">Frasor <italic>et al</italic>., 2008</xref>
###xml 1219 1224 <span type="species:ncbi:9606">human</span>
Estrogens are well documented as having anti-inflammatory effects whereas activated NFkappaB initiates and maintains cellular inflammatory responses (Biswas et al., 2005; Harnish, 2006). Evidence for the anti-inflammatory effects of estrogens was highlighted by the observation that pregnancy reduces the symptoms of rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (Harnish, 2006). One mechanism by which estrogens can modulate inflammatory events has been described in articles documenting that reciprocal inhibitory cross-talk exists between NFkappaB and ER both in vitro (Harnish et al., 2000; Feldman et al., 2007; Quaedackers et al., 2007) and in vivo (Evans et al., 2001). For example, direct interactions between ERalpha and p65 (Quaedackers et al., 2007), as well as cofactor involvement and modulation of IkappaBalpha expression by E2 (Nakshatri et al., 1997; Sun et al., 1998) have been reported. However, more recent studies have also reported that a positive interaction between NFkappaB and ER signalling can occur. For example, Adamson et al. (2008) found that treatment with E2 plus TNFalpha had a synergistic effect on estrogen response element (ERE)-dependent activation of the human prolactin gene in GH3 pituitary cells. Similarly, proinflammatory cytokines (TNFalpha, IL-1beta or IL-6) and E2 also act synergistically to up-regulate expression of prostaglandin E synthase (PGES) mRNA levels in MCF7 breast cancer cells (Frasor et al., 2008). As inflammation and steroid hormone action both play critical roles in endometrial function, we aimed to investigate whether cross-talk between NFkappaB and ER signalling occurs in endometrial epithelial cells and whether this is inhibitory or stimulatory in nature.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and tissue collection
###end title 13
###begin p 14
###xml 21 22 21 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C44">1950</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="DEP421TB1">I</xref>
###xml 48 53 <span type="species:ncbi:9606">women</span>
###xml 118 123 <span type="species:ncbi:9606">women</span>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
Endometrial samples (n = 24) was collected from women undergoing procedures for benign gynaecological conditions. All women had regular menstrual cycles and had not undergone hormonal treatment in the 3 months preceding biopsy. Histological dating of the samples was performed according to the criteria of Noyes (1950). Serum samples collected at the time of endometrial biopsy were used for determination of circulating estradiol and progesterone concentrations by radioimmunoassay (Table I). These circulating steroid hormone levels were consistent with the histological assessment that was undertaken by an expert histologist. Tissues were either fixed in 4% neutral buffered formalin overnight at 4degreesC and embedded in paraffin wax according to standard procedures or placed in RNA Later (Ambion/Applied Biosystems, Warrington, UK) for subsequent RNA extraction. Written informed consent was obtained from all patients and ethical approval was granted by the Lothian research ethics committee.
###end p 14
###begin p 15
Details of endometrial biopsies
###end p 15
###begin p 16
Cycle phase (as determined by the Noyes' criteria) was consistent with circulating estradiol and progesterone concentrations at time of biopsy. PROL = proliferative; ES, MS and LS = early, mid and late secretory; MENST = menstrual.
###end p 16
###begin title 17
Cell culture
###end title 17
###begin p 18
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 231 236 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 214 243 207 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C30">Hombach-Klonisch <italic>et al</italic>., 2005</xref>
###xml 351 352 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 695 700 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 687 707 680 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C43">Nishida <italic>et al</italic>., 1985</xref>
###xml 852 853 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 932 933 918 919 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 424 428 <span type="species:ncbi:9913">calf</span>
###xml 680 685 <span type="species:ncbi:9606">woman</span>
###xml 920 924 <span type="species:ncbi:9913">calf</span>
Telomerase immortalized endometrial epithelial cells (TERT-EEC) were originally derived from normal endometrium obtained during the proliferative phase. These cells express ERalpha, ERbeta and PR mRNA and protein (Hombach-Klonisch et al., 2005; Collins, unpublished). Cells were seeded in 24 well culture plates (Corning-Costar) at a density of 1 x 105/well in Hams F-10 medium supplemented with 10% charcoal stripped fetal calf serum (Sigma, Dorset, UK), insulin-transferrin-selenium (ITS, 1x; Lonza, Slough, UK), penicillin/streptomycin and gentamycin (Sigma). Ishikawa cells (ECACC, Salisbury, UK) were originally derived from the endometrial adenocarcinoma from a 39-year-old woman (Nishida et al., 1985). In our hands, this line of Ishikawa cells expresses ERalpha, ERbeta and PR; cells were seeded in 24 well culture plates at a density of 1 x 105/well in DMEM medium supplemented with 10% charcoal stripped fetal calf serum, l-glutamine, penicillin/streptomycin and non-essential amino acids (1%).
###end p 18
###begin title 19
Luciferase reporter assays
###end title 19
###begin p 20
###xml 229 253 229 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C25">Hall and McDonnell, 1999</xref>
###xml 711 716 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 705 723 681 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C32">Jobin <italic>et al</italic>., 1997</xref>
###xml 735 740 711 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 725 747 701 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C29">Henriksen <italic>et al</italic>., 2004</xref>
An adenoviral vector containing a 3xERE-tk-luciferase reporter gene was prepared by subcloning a piece of DNA containing the ERE promoter and luciferase sequences from a plasmid that was a kind gift from Professor DP McDonnell [(Hall and McDonnell, 1999), Duke University NC, USA] into the adenoviral genome (pBHGloxDeltaE1,3Cre, Microbix) that was propagated in Hek293 cells according to standard methods. An adenovirus containing an NFkappaB response element linked to a luciferase reporter gene was obtained from Vector BioLabs (Philadelphia, USA). The control adenovirus (Ad-d1703) and an adenovirus containing a dominant negative IkappaBalpha mutant (Ad-IkappaBalpha) have been described previously (Jobin et al., 1997; Henriksen et al., 2004). Luciferase was detected using the Bright-Glo luciferase assay system (Promega, Southampton, UK) as detailed in the manufacturer's instructions.
###end p 20
###begin p 21
###xml 109 113 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 346 348 343 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 445 447 442 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 271 508 268 499 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="22">Cells were left untreated or treated with the ER antagonist, ICI 182720 (10<sup>&#8722;6</sup>M), for 1 h. Thereafter cells were either left untreated or incubated with vehicle (DMSO), E2 (10<sup>&#8722;8</sup>M), IL-1&#946; (0.1 ng/ml) or E2 + IL-1&#946; for a further 24 h.</p>
###xml 271 508 268 499 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="22">Cells were left untreated or treated with the ER antagonist, ICI 182720 (10<sup>&#8722;6</sup>M), for 1 h. Thereafter cells were either left untreated or incubated with vehicle (DMSO), E2 (10<sup>&#8722;8</sup>M), IL-1&#946; (0.1 ng/ml) or E2 + IL-1&#946; for a further 24 h.</p></list-item>
###xml 767 769 742 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 508 874 499 843 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="23">Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative I&#954;B&#945; mutant (Ad-I&#954;B&#945;) at a total MOI of 100. The following day, cells were either left untreated or treated with vehicle (DMSO), E2 (10<sup>&#8722;8</sup>M; Sigma), IL-1&#946; (0.1 ng/ml; Peprotech, London, UK) or E2 + IL-1&#946; and incubated for a further 24 h.</p>
###xml 508 874 499 843 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="23">Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative I&#954;B&#945; mutant (Ad-I&#954;B&#945;) at a total MOI of 100. The following day, cells were either left untreated or treated with vehicle (DMSO), E2 (10<sup>&#8722;8</sup>M; Sigma), IL-1&#946; (0.1 ng/ml; Peprotech, London, UK) or E2 + IL-1&#946; and incubated for a further 24 h.</p></list-item>
###xml 1186 1187 1131 1132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 1234 1239 1179 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1224 1246 1169 1191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C36">Kraichely <italic>et al</italic>., 2000</xref>
###xml 1254 1256 1199 1201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1341 1346 1283 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1334 1353 1276 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C40">Meyers <italic>et al</italic>., 2001</xref>
###xml 1361 1363 1303 1305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 874 1460 843 1396 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="24">Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative I&#954;B&#945; mutant (Ad-I&#954;B&#945;) at a total MOI of 100. Cells were either left untreated or treated with vehicle (DMSO), IL-1&#946; (0.l ng/ml), the ER&#945; selective agonist, PPT (4,4&#8242;,4&#8243;-(4-propyl-[<sup>1</sup>H]-pyrazole-1,3,5-triyl tris-phenol (<xref ref-type="bibr" rid="DEP421C36">Kraichely <italic>et al</italic>., 2000</xref>)) at 10<sup>&#8722;8</sup>M, the ER&#946; selective agonist, DPN (2,3-bis(4-hydroxyphenyl)-propionitrile (<xref ref-type="bibr" rid="DEP421C40">Meyers <italic>et al</italic>., 2001</xref>)) at 10<sup>&#8722;7</sup>M, or combinations of these treatments (PPT + IL-1&#946; or DPN + IL-1&#946;) and incubated for 24 h.</p>
###xml 874 1460 843 1396 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="24">Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative I&#954;B&#945; mutant (Ad-I&#954;B&#945;) at a total MOI of 100. Cells were either left untreated or treated with vehicle (DMSO), IL-1&#946; (0.l ng/ml), the ER&#945; selective agonist, PPT (4,4&#8242;,4&#8243;-(4-propyl-[<sup>1</sup>H]-pyrazole-1,3,5-triyl tris-phenol (<xref ref-type="bibr" rid="DEP421C36">Kraichely <italic>et al</italic>., 2000</xref>)) at 10<sup>&#8722;8</sup>M, the ER&#946; selective agonist, DPN (2,3-bis(4-hydroxyphenyl)-propionitrile (<xref ref-type="bibr" rid="DEP421C40">Meyers <italic>et al</italic>., 2001</xref>)) at 10<sup>&#8722;7</sup>M, or combinations of these treatments (PPT + IL-1&#946; or DPN + IL-1&#946;) and incubated for 24 h.</p></list-item>
###xml 271 1460 268 1396 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="roman-lower"><list-item><p textid="22">Cells were left untreated or treated with the ER antagonist, ICI 182720 (10<sup>&#8722;6</sup>M), for 1 h. Thereafter cells were either left untreated or incubated with vehicle (DMSO), E2 (10<sup>&#8722;8</sup>M), IL-1&#946; (0.1 ng/ml) or E2 + IL-1&#946; for a further 24 h.</p></list-item><list-item><p textid="23">Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative I&#954;B&#945; mutant (Ad-I&#954;B&#945;) at a total MOI of 100. The following day, cells were either left untreated or treated with vehicle (DMSO), E2 (10<sup>&#8722;8</sup>M; Sigma), IL-1&#946; (0.1 ng/ml; Peprotech, London, UK) or E2 + IL-1&#946; and incubated for a further 24 h.</p></list-item><list-item><p textid="24">Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative I&#954;B&#945; mutant (Ad-I&#954;B&#945;) at a total MOI of 100. Cells were either left untreated or treated with vehicle (DMSO), IL-1&#946; (0.l ng/ml), the ER&#945; selective agonist, PPT (4,4&#8242;,4&#8243;-(4-propyl-[<sup>1</sup>H]-pyrazole-1,3,5-triyl tris-phenol (<xref ref-type="bibr" rid="DEP421C36">Kraichely <italic>et al</italic>., 2000</xref>)) at 10<sup>&#8722;8</sup>M, the ER&#946; selective agonist, DPN (2,3-bis(4-hydroxyphenyl)-propionitrile (<xref ref-type="bibr" rid="DEP421C40">Meyers <italic>et al</italic>., 2001</xref>)) at 10<sup>&#8722;7</sup>M, or combinations of these treatments (PPT + IL-1&#946; or DPN + IL-1&#946;) and incubated for 24 h.</p></list-item></list>
Three separate experimental protocols were used to examine the effects of E2 and IL-1beta on ERE activity in TERT-EEC. In all experiments, cells were infected with adenovirus containing the ERE-luc expression construct. The total multiplicity of infection (MOI) was 100. Cells were left untreated or treated with the ER antagonist, ICI 182720 (10-6M), for 1 h. Thereafter cells were either left untreated or incubated with vehicle (DMSO), E2 (10-8M), IL-1beta (0.1 ng/ml) or E2 + IL-1beta for a further 24 h.Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative IkappaBalpha mutant (Ad-IkappaBalpha) at a total MOI of 100. The following day, cells were either left untreated or treated with vehicle (DMSO), E2 (10-8M; Sigma), IL-1beta (0.1 ng/ml; Peprotech, London, UK) or E2 + IL-1beta and incubated for a further 24 h.Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative IkappaBalpha mutant (Ad-IkappaBalpha) at a total MOI of 100. Cells were either left untreated or treated with vehicle (DMSO), IL-1beta (0.l ng/ml), the ERalpha selective agonist, PPT (4,4',4''-(4-propyl-[1H]-pyrazole-1,3,5-triyl tris-phenol (Kraichely et al., 2000)) at 10-8M, the ERbeta selective agonist, DPN (2,3-bis(4-hydroxyphenyl)-propionitrile (Meyers et al., 2001)) at 10-7M, or combinations of these treatments (PPT + IL-1beta or DPN + IL-1beta) and incubated for 24 h.Concentrations of E2, PPT and DPN used were those found to give an optimal response in the ERE reporter assay in pilot studies. In additional complementary experiments, Ishikawa cells were infected with ERE and either Ad-d1703 or Ad-IkappaBalpha (total MOI = 50) and treated as in (ii).
###end p 21
###begin p 22
###xml 75 77 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
Cells were left untreated or treated with the ER antagonist, ICI 182720 (10-6M), for 1 h. Thereafter cells were either left untreated or incubated with vehicle (DMSO), E2 (10-8M), IL-1beta (0.1 ng/ml) or E2 + IL-1beta for a further 24 h.
###end p 22
###begin p 23
###xml 259 261 243 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative IkappaBalpha mutant (Ad-IkappaBalpha) at a total MOI of 100. The following day, cells were either left untreated or treated with vehicle (DMSO), E2 (10-8M; Sigma), IL-1beta (0.1 ng/ml; Peprotech, London, UK) or E2 + IL-1beta and incubated for a further 24 h.
###end p 23
###begin p 24
###xml 312 313 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 360 365 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 350 372 326 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C36">Kraichely <italic>et al</italic>., 2000</xref>
###xml 380 382 356 358 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 467 472 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 460 479 433 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C40">Meyers <italic>et al</italic>., 2001</xref>
###xml 487 489 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
Cells were co-infected with a control adenovirus (Ad-d1703) or an adenovirus containing a dominant negative IkappaBalpha mutant (Ad-IkappaBalpha) at a total MOI of 100. Cells were either left untreated or treated with vehicle (DMSO), IL-1beta (0.l ng/ml), the ERalpha selective agonist, PPT (4,4',4''-(4-propyl-[1H]-pyrazole-1,3,5-triyl tris-phenol (Kraichely et al., 2000)) at 10-8M, the ERbeta selective agonist, DPN (2,3-bis(4-hydroxyphenyl)-propionitrile (Meyers et al., 2001)) at 10-7M, or combinations of these treatments (PPT + IL-1beta or DPN + IL-1beta) and incubated for 24 h.
###end p 24
###begin p 25
###xml 78 82 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 175 177 167 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
The impact of treatments on NFkappaB signalling was investigated by infecting TERT-EECs with the NFkappaB-luc reporter at an MOI of 50; cells were treated with vehicle, E2 (10-8M), IL-1beta (0.1 ng/ml) or E2 + IL-1beta for 24 h. Each experiment was repeated on three separate occasions.
###end p 25
###begin title 26
Endogenous gene expression
###end title 26
###begin p 27
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 295 297 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 142 146 <span type="species:ncbi:9913">calf</span>
TERT-EEC were seeded in six well culture plates at a density of 3 x 105/well in Hams-F10 medium supplemented with 10% charcoal stripped fetal calf serum, ITS (1x), penicillin/streptomycin and gentamycin. The following day cells were either left untreated or incubated with vehicle (DMSO), E2 (10-8M), IL-1beta (0.lng/ml) or both factors at the same time for 2, 4 and 8 h. The experiment was repeated three times.
###end p 27
###begin title 28
Quantitative RT-PCR
###end title 28
###begin p 29
###xml 635 636 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
RNA was extracted from cells or endometrial tissues using RNeasy mini kits (Qiagen,); RNA samples were treated with DNase I. Complementary DNA was prepared from 400 ng of template RNA in 20 microl reactions containing: RT buffer (1x), magnesium chloride (5.5 mM), dNTP mix (2 mM), random hexamers (2.5 microM), RNase inhibitor (0.4 U/microl) and Multiscribe reverse transcriptase (1.25 U/microl; Applied Biosystems, Cheshire, UK). Each cDNA preparation included two controls: one containing template RNA but no reverse transcriptase (RT negative) and the other containing reverse transcriptase with water in place of template RNA (RT H2O).
###end p 29
###begin p 30
###xml 380 393 380 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;&#916;&#916;Ct</sup>
PCR reaction mixtures contained Taqman Master-mix (1x; Applied Biosystems), forward and reverse primers (Eurogentec) and probe (Eurogentec/Roche) for the gene of interest and forward and reverse primers and probe for ribosomal 18s (Applied Biosystems). Expression of the gene of interest was related to expression of 18S ribosomal RNA and to an internal control sample using the 2-DeltaDeltaCt method. Controls included the RT controls detailed above and a PCR no template control (water in place of cDNA). PCR reactions were run on an ABI 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems, USA). Primer and probe sequences are detailed in .
###end p 30
###begin title 31
Immunohistochemistry
###end title 31
###begin p 32
###xml 97 98 89 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 593 599 <span type="species:ncbi:9986">rabbit</span>
###xml 630 636 <span type="species:ncbi:9986">rabbit</span>
###xml 678 684 <span type="species:ncbi:9986">rabbit</span>
###xml 924 928 <span type="species:ncbi:9925">goat</span>
###xml 934 940 <span type="species:ncbi:9986">rabbit</span>
Immunohistochemical localization of p65, p105/p50 and IkappaBalpha was performed on endometrial (n = 17) sections as follows. Antigen retrieval was carried out using a microwave (15 min in antigen unmasking solution, Vector, Peterborough, UK); endogenous peroxidase activity was blocked with 3% hydrogen peroxide (Sigma-Aldrich, Dorset, UK). Additional pretreatments involved incubation with solutions from the avidin biotin blocking kit (Vector) and the DakoCytomation protein block (Dako, Ely, UK), 10 min each at room temperature. Sections were incubated overnight at 4degreesC with either rabbit-anti p65 (1:500; Santa Cruz), rabbit anti-p105/50 (1:500; NLS, Santa Cruz) or rabbit anti-IkappaBalpha (1:300; E130, Abcam, Cambridge, UK) diluted in REAL antibody diluent (Dako). For negative controls, the primary antibody was substituted with antibody diluent alone. Sections were washed and incubated with a biotinylated goat anti-rabbit secondary antibody and the avidin biotin peroxidase detection system, both for 30 min at room temperature (Vectastain Elite ABC, Vector). Positive staining was detected using diaminobenzidine (ImmPACT DAB; Vector) and sections were counterstained with Harris' haematoxylin.
###end p 32
###begin title 33
Statistics
###end title 33
###begin p 34
###xml 111 119 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 820 828 814 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
Significant differences in mRNA expression in endometrial biopsies was determined by one-way ANOVA and Tukey's post hoc analysis. These data were logarithmically transformed prior to statistical analysis. Data from reporter assays were statistically analysed using repeated measures two-way ANOVA and Bonferroni's post hoc analysis. Vehicle treatments are not shown in figures as there was no statistical difference between vehicle and control (without vehicle) samples in any of the experiments. Fold changes quoted in the results section were calculated by comparison to the untreated control for IL-1beta and by comparison to DMSO (vehicle control) for E2 and E2 + IL-1beta. Significant differences in mRNA expression in cell culture experiments were determined using repeated measures two-way ANOVA and Bonferroni's post hoc analysis.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
Expression of p65 and p105 mRNA in endometrium is highest during the secretory phase of the menstrual cycle
###end title 36
###begin p 37
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F1">1</xref>
###xml 166 167 166 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F1">1</xref>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Quantitative RT-PCR analysis of well characterized endometrial biopsies showed that p65 mRNA expression is highest during the mid and late secretory phases (Fig. 1A; P < 0.05). p105 mRNA expression peaks during the late secretory phase of the menstrual cycle (Fig. 1B; P < 0.05).
###end p 37
###begin p 38
Differential mRNA expression of p65 and p105 in endometrium from throughout the menstrual cycle.
###end p 38
###begin title 39
###xml 59 64 <span type="species:ncbi:9606">human</span>
p65, p105/p50 and IkappaBalpha are widely expressed in the human endometrium and are present in both epithelial and stromal compartments
###end title 39
###begin p 40
###xml 122 123 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F2">2</xref>
Immunoexpression of p65, p105/p50 and IkappaBalpha was detected in endometrium at all stages of the menstrual cycle (Fig. 2: shows immunolocalization in a representative endometrial biopsy from the mid secretory phase). There were no obvious changes to the pattern of localization at different menstrual cycle phases (data not shown). Cytoplasmic staining was detected in both glandular and stromal compartments as well as in endothelial cells surrounding the blood vessels.
###end p 40
###begin p 41
Immunolocalization of p65, p105/p50 and IkappaBalpha in endometrium from the mid secretory phase of the menstrual cycle.
###end p 41
###begin title 42
IL-1beta and E2 interact to enhance ERE-dependent reporter gene activity in endometrial epithelial cells and this is ER dependent
###end title 42
###begin p 43
###xml 235 236 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Initial studies conducted using endometrial adenocarcinoma Ishikawa cells showed that treatment with E2 raised ERE activity 4-fold whereas addition of IL-1beta alone or in combination with E2 had no impact on reporter gene activity (; P < 0.01).
###end p 43
###begin p 44
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F3">3</xref>
###xml 346 347 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F3">3</xref>
###xml 349 350 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 434 438 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
Incubation of TERT-EECs with 10-8M E2 resulted in a 5-fold increase in the ERE-dependent expression of luciferase (Fig. 3). In contrast with the Ishikawa cells, increased expression was also observed when cells were treated with IL-1beta alone and simultaneous exposure to E2 and IL-1beta increased ERE-luciferase reporter activity 15-fold (Fig. 3; P < 0.01). Both basal ERE activity and the increased ERE activity that occurred when TERT-EEC were treated with E2, IL-1beta or E2 + IL-1beta were abolished by the presence of the ER antagonist, ICI 182720.
###end p 44
###begin p 45
###xml 137 141 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
E2 and IL-1beta positively interact to enhance estrogen response element (ERE) activity in an estrogen receptor (ER) dependent manner in TERT-EECs.
###end p 45
###begin p 46
###xml 80 84 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
In complementary studies, NFkappaB response element activity was increased when TERT-EEC were incubated with IL-1beta alone. However, incubation with E2 had no impact on expression of the luciferase reporter and there was no evidence of an additive or synergistic effect when cells were co-incubated with E2 and IL-1beta (data not shown).
###end p 46
###begin title 47
Activation of ERE-dependent reporter gene activity by IL-1beta is NFkappaB-dependent and the interaction between NFkappaB and ER signalling pathways may be mediated by either ERalpha or ERbeta
###end title 47
###begin p 48
###xml 251 252 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F4">4</xref>
In a similar experiment assessing ERE activation, the presence of a dominant negative IkappaBalpha molecule reduced IL-1beta-dependent increases in ERE-luciferase gene expression when cells were incubated with IL-1beta alone or IL-1beta plus E2 (Fig. 4A).
###end p 48
###begin p 49
###xml 52 56 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
The positive interaction between E2 and IL-1beta in TERT-EECs is NFkappaB dependent and can be mediated by ERalpha and ERbeta.
###end p 49
###begin p 50
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 322 323 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F4">4</xref>
###xml 326 327 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Treatment of TERT-EEC with the ERalpha selective agonist, PPT, or the ERbeta selective agonist, DPN, increased ERE-luciferase reporter gene expression 5-fold and 4-fold, respectively. When the cells were treated with IL-1beta in combination with PPT or DPN, ERE activity was raised 13-fold and 12-fold, respectively (Fig. 4B; P < 0.001), and these additive interactions were reduced by the presence of Ad-IkappaBalpha.
###end p 50
###begin title 51
IL-1beta and E2 act additively to enhance expression of PGES and c-myc
###end title 51
###begin p 52
###xml 16 19 16 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A+B</sub>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 107 110 107 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A+B</sub>
###xml 246 247 243 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F5">5</xref>
###xml 250 251 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 427 428 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F5">5</xref>
###xml 431 432 425 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 536 540 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 717 718 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F5">5</xref>
###xml 721 722 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 942 943 924 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F5">5</xref>
###xml 946 947 928 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Expression of PRA+B, c-myc, PGES and cyclin D1 in TERT-EEC was examined after 2, 4 and 8 h of treatment. PRA+B mRNA expression was significantly increased by treatment with E2 at 4 and 8 h and this was unaffected by treatment with IL-1beta (Fig. 5A; P < 0.05). c-myc mRNA expression was up-regulated 3.4-fold by treatment with E2 alone at 8 h and this increase was enhanced in the presence of IL-1beta (6.7-fold increase, Fig. 5B; P < 0.05). Treatment with IL-1beta alone did not alter c-myc mRNA expression. Expression of PGES mRNA in TERT-EEC was increased 2.7-fold and 4.8-fold by treatment with E2 and IL-1beta for 8 h, respectively. E2 and IL-1beta acted together to raise PGES mRNA expression by 9.5-fold (Fig. 5C; P < 0.001). Similar effects of treatment were observed at 4 h. In contrast, cyclin D1 mRNA expression was increased 1.6-fold by treatment with E2 at 8 h and this response was not altered by the presence of IL-1beta (Fig. 5D; P < 0.01).
###end p 52
###begin p 53
###xml 63 67 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
Regulation of endogenous gene expression by E2 and IL-1beta in TERT-EECs.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 211 216 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 194 223 190 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C30">Hombach-Klonisch <italic>et al</italic>., 2005</xref>
To our knowledge, we report novel data detailing an additive interaction between the ER and NFkappaB signalling pathways in endometrial epithelial cells derived from normal healthy endometrium (Hombach-Klonisch et al., 2005). The increase in ERE activity could be mediated by either ERalpha or ERbeta.
###end p 55
###begin p 56
###xml 176 184 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 202 207 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 194 214 186 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C27">Harnish <italic>et al</italic>., 2000</xref>
###xml 224 229 216 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 216 236 208 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C20">Feldman <italic>et al</italic>., 2007</xref>
###xml 250 255 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 238 262 230 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C47">Quaedackers <italic>et al</italic>., 2007</xref>
###xml 360 365 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 348 372 340 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C47">Quaedackers <italic>et al</italic>., 2007</xref>
###xml 405 410 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 397 417 389 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C27">Harnish <italic>et al</italic>., 2000</xref>
###xml 425 430 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 419 437 411 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C52">Speir <italic>et al</italic>., 2000</xref>
###xml 494 499 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 490 506 474 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C53">Sun <italic>et al</italic>., 1998</xref>
###xml 655 660 635 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 643 667 623 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C47">Quaedackers <italic>et al</italic>., 2007</xref>
###xml 754 759 726 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 750 766 722 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C53">Sun <italic>et al</italic>., 1998</xref>
###xml 928 933 896 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 920 940 888 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C27">Harnish <italic>et al</italic>., 2000</xref>
###xml 948 953 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 942 960 910 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C52">Speir <italic>et al</italic>., 2000</xref>
###xml 1040 1047 1004 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vivo</italic>
###xml 1093 1099 1057 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1143 1148 1107 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1151 1155 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C20">2007</xref>
###xml 1528 1533 1481 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1510 1540 1463 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C24">Guzeloglu-Kayisli <italic>et al</italic>., 2008</xref>
###xml 1803 1807 1749 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 860 865 <span type="species:ncbi:9606">human</span>
###xml 1048 1053 <span type="species:ncbi:10090">mouse</span>
Previous studies have reported negative interactions between the ER and NFkappaB pathways. Mutual repression of signalling between NFkappaB and ER has been reported in various in-vitro systems (Harnish et al., 2000; Feldman et al., 2007; Quaedackers et al., 2007). A number of different mechanisms including direct interactions between p65 and ER (Quaedackers et al., 2007), cofactor recruitment (Harnish et al., 2000; Speir et al., 2000) and E2-mediated modulation of IkappaBalpha levels (Sun et al., 1998) have been suggested to explain these results. Direct interactions between ERalpha and p65 have been shown in osteoblastic U2-OS cells (Quaedackers et al., 2007) although E2 prevents degradation of IkappaBalpha by PMA treatment of HeLa cells (Sun et al., 1998). The cofactors CBP and p300 are reported to mediate interactions between NFkappaB and ER in human liver and coronary smooth muscle cells, respectively (Harnish et al., 2000; Speir et al., 2000). Mutual inhibition of NFkappaB and ER signalling has also been detailed in an in-vivo mouse model of cardiovascular disease (Evans et al., 2001). In a reproductive context, Feldman et al. (2007) have shown that IL-1beta inhibits ERE activity in Ishikawa cells in the presence of E2 after a 48 h treatment period and have suggested that there is also a reciprocal inhibitory action of E2 on NFkappaB activity. In addition, it has also been reported that NFkappaB activation reduces the response of both Ishikawa and endometrial stromal cells to E2 (Guzeloglu-Kayisli et al., 2008). In our current study, we did not find any effect of IL-1beta on ERE activity in Ishikawa cells in the absence or presence of E2 at a 24 h time point. These results are in contrast to the additive interaction that occurs between the ER and NFkappaB pathways in TERT-EECs, suggesting that the relationship between these two signalling pathways is cell-type specific. This may be reflective of differences between cells derived from the healthy endometrial epithelium and those derived from adenocarcinomas or the stromal compartment and highlights the importance of using untransformed cells to model normal endometrial cell function.
###end p 56
###begin p 57
###xml 130 135 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 138 142 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C21">2008</xref>
###xml 500 504 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 611 619 589 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 970 974 940 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 1147 1152 1113 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1139 1159 1105 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C3">Adamson <italic>et al</italic>., 2008</xref>
###xml 1498 1503 1452 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1490 1510 1444 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C3">Adamson <italic>et al</italic>., 2008</xref>
###xml 985 990 <span type="species:ncbi:9606">human</span>
Positive interactions between the ER and NFkappaB signalling pathways have been described in some cell lines. For example, Frasor et al. (2008) reported that E2 and TNFalpha or IL-1beta act in synergy to up-regulate PGES expression in the MCF-7 breast cancer cell line by an ER- and NFkappaB-dependent mechanism, which involves increased recruitment of both ERalpha and p65 to the ERE in the PGES promoter. In the present study, we demonstrated that expression of PGES was markedly up-regulated when TERT-EEC were incubated with E2 and IL-1beta, suggesting that p65 recruitment to the ERE may also occur in our in-vitro model. Alternatively interactions between NFkappaB and ER may be mediated via one of the mechanisms that have been documented to occur when there is a negative interaction between these signalling pathways (as detailed above). Further studies are necessary to determine the molecular basis for the interaction between the ER and NFkappaB pathways in TERT-EECs. The human prolactin promoter contains a functional ERE and is synergistically activated by E2 and TNFalpha in a reporter assay via an ER-dependent mechanism (Adamson et al., 2008). Endogenous prolactin gene expression was also increased synergistically by E2 and TNFalpha in that study. However, a reporter assay using a consensus ERE-construct showed that TNFalpha inhibited ERE activity in this case suggesting that the synergistic interaction between TNFalpha and ER is specific to the prolactin promoter (Adamson et al., 2008).
###end p 57
###begin p 58
###xml 198 202 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 469 474 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 463 482 456 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C16">Duyao <italic>et al</italic>., 1990a</xref>
###xml 484 485 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C17">b</xref>
###xml 497 502 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 487 509 480 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C23">Guttridge <italic>et al</italic>., 1999</xref>
###xml 523 528 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 511 535 504 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C54">Takebayashi <italic>et al</italic>., 2003</xref>
###xml 544 549 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 537 556 530 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C49">Saitoh <italic>et al</italic>., 2005</xref>
###xml 565 570 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 558 577 551 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C11">Condon <italic>et al</italic>., 2006</xref>
###xml 588 593 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 579 600 572 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C2">Ackerman <italic>et al</italic>., 2008</xref>
###xml 822 827 815 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 815 834 808 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C22">Gruber <italic>et al</italic>., 2004</xref>
###xml 935 940 928 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 923 947 916 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C10">Chauchereau <italic>et al</italic>., 1991</xref>
###xml 954 959 947 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 949 966 942 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C46">Petz <italic>et al</italic>., 2004</xref>
###xml 1157 1177 1150 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C15">Dubik and Shiu, 1992</xref>
###xml 1287 1292 1280 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1280 1299 1273 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C21">Frasor <italic>et al</italic>., 2008</xref>
###xml 1443 1448 1432 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1429 1455 1418 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C9">Castro-Rivera <italic>et al</italic>., 2001</xref>
###xml 1463 1468 1452 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1457 1475 1446 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C48">Rubio <italic>et al</italic>., 2006</xref>
We found evidence of an additive interaction between E2 and IL-1beta regulated expression of PGES and c-myc, but the same treatment did not have a similar impact on expression of PR or cyclin D1 in TERT-EEC. We suggest that these differences are due to the presence of different response elements in the promoter region of each gene. In this context, previous studies have suggested that promoter elements within each of these genes can be regulated by NFkappaB (Duyao et al., 1990a, b; Guttridge et al., 1999; Takebayashi et al., 2003; Saitoh et al., 2005; Condon et al., 2006; Ackerman et al., 2008) but that their regulation by E2 is more complex. Notably ligand-activated ERs can regulate gene expression directly via an ERE or indirectly by interacting with other transcription factors including AP-1 and Sp1 (Gruber et al., 2004). ER-dependent regulation of PR is reported to be mediated by both EREs and a Sp1 site (Chauchereau et al., 1991; Petz et al., 2004). Although c-myc is considered to be an E2-regulated early response gene, its promoter does not contain a consensus ERE but its E2 responsiveness is reported to be mediated via Sp1 binding (Dubik and Shiu, 1992). The PGES promoter is reported to contain a functional ERE upstream of the transcription start site (Frasor et al., 2008) although the responsiveness of cyclin D1 to E2 is reported to involve AP-1, Sp1 and NFkappaB sites rather than a consensus ERE (Castro-Rivera et al., 2001; Rubio et al., 2006).
###end p 58
###begin p 59
###xml 389 394 373 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 383 401 367 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C48">Rubio <italic>et al</italic>., 2006</xref>
###xml 753 758 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 745 765 713 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C58">Wissink <italic>et al</italic>., 2001</xref>
###xml 907 911 871 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
A positive interaction between the ER- and NFkappaB-signalling pathways has also been reported to occur at kappaB sites. In the T47D breast cancer cell line, E2 induces proliferation and cyclin D1 expression by an NFkappaB dependent mechanism, which is enhanced in the presence of TNFalpha and involves the formation of a protein complex containing ER, p65 and the coactivator RAC3 (Rubio et al., 2006). In COS-1 cells, ERalpha and NFkappaB have also been found to have a synergistic action at the 5-HT1A receptor promoter via NFkappaB sites, although this study also showed that E2 represses the activity of an NFkappaB response element in a synthetic construct, again suggesting that the interaction between the pathways is promoter specific (Wissink et al., 2001). In contrast, in our current study, we have not found any evidence for a positive or negative effect of E2 on NFkappaB reporter activity in TERT-EECs (data not shown).
###end p 59
###begin p 60
###xml 240 245 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 230 252 227 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C14">Critchley <italic>et al</italic>., 2002</xref>
###xml 262 267 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 254 274 251 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C7">Bombail <italic>et al</italic>., 2008</xref>
###xml 701 706 675 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 696 713 670 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C35">King <italic>et al</italic>., 2001</xref>
###xml 830 835 804 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 824 842 798 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C37">Laird <italic>et al</italic>., 2000</xref>
###xml 849 854 823 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 844 861 818 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C45">Page <italic>et al</italic>., 2002</xref>
###xml 1349 1354 1323 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1342 1361 1316 1335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C8">Bulmer <italic>et al</italic>., 1991</xref>
During the putative implantation window, immunoexpression studies have revealed that ERbeta is the predominant ER protein present in the nuclei of glandular and surface epithelial cells in the functional layer of the endometrium (Critchley et al., 2002; Bombail et al., 2008). In the present study, we detected immunoexpression of the NFkappaB proteins, p65 and p50, in the glandular epithelium in endometrium along with the inhibitor protein, IkappaBalpha. Our previous studies have also demonstrated the presence of mRNA for the upstream kinases MEKK1, NIK, IKKalpha and IKKbeta in endometrium with MEKK1 and IKKalpha proteins localized to the glandular and, in some cases luminal, epithelium (King et al., 2001). The expression of p65 and p50 has previously been reported to peak around the putative implantation window (Laird et al., 2000; Page et al., 2002) on the basis of semi-quantitative immunohistochemical studies. Our current quantitative analysis of p65 and p105 mRNA expression in well characterized endometrial biopsies is in agreement. It should be noted that these quantitative PCR studies do not provide information regarding which cellular compartment(s) are responsible for the increased expression of p65 and p105 mRNA in the secretory phase. Leukocyte populations present in endometrium vary across the menstrual cycle (Bulmer et al., 1991) and may contribute to the changes we have documented. In any case, our current data, along with that previously reported by others, suggest that the NFkappaB pathway may be involved in the regulation of inflammatory events at implantation.
###end p 60
###begin p 61
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 119 137 119 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C51">Simon <italic>et al</italic>., 1997</xref>
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 139 161 139 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C19">Fazleabas <italic>et al</italic>., 2004</xref>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 221 241 221 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C4">Baranao <italic>et al</italic>., 1997</xref>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 310 333 310 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C5">Bigonnesse <italic>et al</italic>., 2001</xref>
###xml 418 423 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 412 430 412 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C50">Simon <italic>et al</italic>., 1994</xref>
###xml 501 506 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 490 513 490 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C1">Abbondanzo <italic>et al</italic>., 1996</xref>
###xml 603 610 603 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 786 787 786 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="DEP421F6">6</xref>
###xml 927 932 927 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 921 939 921 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C33">Jones <italic>et al</italic>., 1997</xref>
###xml 941 969 941 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C39">Marions and Danielsson, 1999</xref>
###xml 977 982 977 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 971 989 971 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C41">Milne <italic>et al</italic>., 2001</xref>
###xml 1123 1128 1123 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1114 1135 1114 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C55">Tranguch <italic>et al</italic>., 2005</xref>
###xml 1145 1150 1145 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1137 1157 1137 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C34">Kennedy <italic>et al</italic>., 2007</xref>
###xml 1250 1251 1247 1248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1588 1593 1581 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1583 1600 1576 1593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="DEP421C57">Wang <italic>et al</italic>., 1998</xref>
###xml 1616 1620 1609 1613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT</italic>
###xml 1688 1696 1681 1689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 1766 1773 1759 1766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
###xml 860 865 <span type="species:ncbi:9606">human</span>
The IL-1 system is a key cytokine network that has an impact on endometrial cell function at the time of implantation (Simon et al., 1997; Fazleabas et al., 2004). Notably, IL-1 is produced by the preimplantation embryo (Baranao et al., 1997) and the IL-1 receptor type I is present in endometrial epithelium (Bigonnesse et al., 2001). An IL-1 receptor antagonist has been shown to prevent implantation in mice (Simon et al., 1994) although a further study did not report a similar effect (Abbondanzo et al., 1996). Our data suggest that IL-1 may augment the actions of E2 on the endometrial epithelium in vivo. This could be a mechanism to allow the developing blastocyst to modulate the function of the endometrial epithelium enhancing the likelihood of successful implantation (Fig. 6). For example, both cyclo-oxygenase and PGES enzymes are present in the human endometrial epithelium during the implantation window (Jones et al., 1997; Marions and Danielsson, 1999; Milne et al., 2001). Prostaglandins increase vascular permeability, modulate decidualization and regulate the immune response at implantation (Tranguch et al., 2005; Kennedy et al., 2007). Our data suggest that E2 and IL-1beta may act additively to increase the production of PGE2 by up-regulating PGES expression in the endometrial epithelium. We recognize that progesterone may also impact the ER and NFkappaB signalling pathways at implantation. However, the endometrial epithelium does not express the PR during the implantation window, so progesterone actions would be mediated via the stromal compartment (Wang et al., 1998). Although the TERT-EECs do express the PR, examination of progesterone effects in our in-vitro epithelial cell model would not be representative of the environment in vivo.
###end p 61
###begin p 62
Summary of the potential interactions between the ER and NFkappaB signalling pathways in endometrial epithelial cells.
###end p 62
###begin p 63
###xml 338 346 326 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 347 352 <span type="species:ncbi:9606">human</span>
In summary, we have identified a novel positive interaction between the ER- and NFkappaB-dependent signalling pathways in an endometrial epithelial cell line derived from healthy endometrium. NFkappaB activation modulates ERE activity by an ER and NFkappaB dependent mechanism and can enhance ER-mediated endogenous gene expression in an in-vitro human endometrial epithelial cell model. The positive interaction between NFkappaB and ER may be involved in the regulation of epithelial cell function at implantation and aberrant interactions between these signalling pathways may be involved in pathologies such as early pregnancy failure and infertility.
###end p 63
###begin title 64
Supplementary data
###end title 64
###begin p 65
.
###end p 65
###begin title 66
Authors' Roles
###end title 66
###begin p 67
A.E.K., F.C.: laboratory work, data analysis, manuscript preparation. T.K., J.-M.S.: manuscript preparation. H.O.D.C.: data analysis, manuscript preparation. P.T.K.S.: study design, data analysis, manuscript preparation.
###end p 67
###begin title 68
Funding
###end title 68
###begin p 69
###xml 35 65 35 65 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Caledonian Research Foundation</funding-source>
###xml 251 264 251 264 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MRC programme</funding-source>
###xml 271 279 271 279 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G0500047</award-id>
This research was supported by the Caledonian Research Foundation (personal research fellowship to Dr Anne King), the Barbour Watson Fund and Tenovus, Scotland. PTKS and FC were supported by MRC programme U.1276.00.002.00005.01. HODC was supported by MRC programme grant G0500047.
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[Supplementary Data]
###end title 71
###begin title 72
Acknowledgements
###end title 72
###begin p 73
###xml 90 97 <span type="species:ncbi:9606">patient</span>
We thank our research nurses Catherine Murray, Catherine Cairns and Sharon MacPherson for patient recruitment and assistance with biopsy collection, Pamela Brown for preparation of viral constructs, Amirah Mohamed for technical assistance and Ronnie Grant for graphical assistance.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
###xml 16 20 <span type="species:ncbi:10090">mice</span>
Reproduction in mice lacking a functional type 1 IL-1 receptor
###end article-title 75
###begin article-title 76
###xml 82 87 <span type="species:ncbi:9606">human</span>
Nuclear factor-kappa B regulates inducible prostaglandin E synthase expression in human amnion mesenchymal cells
###end article-title 76
###begin article-title 77
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling
###end article-title 77
###begin article-title 78
###xml 41 46 <span type="species:ncbi:9606">human</span>
Determination of IL-1 and IL-6 levels in human embryo culture-conditioned media
###end article-title 78
###begin article-title 79
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 117 122 <span type="species:ncbi:9606">women</span>
###xml 127 132 <span type="species:ncbi:9606">women</span>
Triphasic expression of interleukin-1 receptor type I in human endometrium throughout the menstrual cycle of fertile women and women with unexplained infertility
###end article-title 79
###begin article-title 80
Crossroads of estrogen receptor and NF-kappaB signaling
###end article-title 80
###begin article-title 81
###xml 47 52 <span type="species:ncbi:9606">human</span>
Estrogen receptor related beta is expressed in human endometrium throughout the normal menstrual cycle
###end article-title 81
###begin article-title 82
Leukocytes and resident blood cells in endometrium
###end article-title 82
###begin article-title 83
Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements
###end article-title 83
###begin article-title 84
Phosphorylation of transfected wild type and mutated progesterone receptors
###end article-title 84
###begin article-title 85
Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function
###end article-title 85
###begin article-title 86
###xml 41 46 <span type="species:ncbi:9606">human</span>
Hormone receptor dynamics in a receptive human endometrium
###end article-title 86
###begin article-title 87
###xml 103 108 <span type="species:ncbi:9606">human</span>
Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium
###end article-title 87
###begin article-title 88
###xml 108 113 <span type="species:ncbi:9606">human</span>
Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle
###end article-title 88
###begin article-title 89
Dubik D and Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression
###end article-title 89
###begin article-title 90
Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter
###end article-title 90
###begin article-title 91
Binding of NF-KB-like factors to regulatory sequences of the c-myc gene
###end article-title 91
###begin article-title 92
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo
###end article-title 92
###begin article-title 93
Implantation: embryonic signals and the modulation of the uterine environment-a review
###end article-title 93
###begin article-title 94
Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha
###end article-title 94
###begin article-title 95
Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines
###end article-title 95
###begin article-title 96
Anatomy of the estrogen response element
###end article-title 96
###begin article-title 97
NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1
###end article-title 97
###begin article-title 98
DNA-binding ability of NF-kappaB is affected differently by ERalpha and ERbeta and its activation results in inhibition of estrogen responsiveness
###end article-title 98
###begin article-title 99
###xml 51 56 <span type="species:ncbi:9606">human</span>
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
###end article-title 99
###begin article-title 100
Estrogen receptor ligands in the control of pathogenic inflammation
###end article-title 100
###begin article-title 101
The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells
###end article-title 101
###begin article-title 102
Steroid receptor expression in uterine natural killer cells
###end article-title 102
###begin article-title 103
###xml 136 141 <span type="species:ncbi:9606">human</span>
Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli
###end article-title 103
###begin article-title 104
###xml 99 104 <span type="species:ncbi:9606">human</span>
Regulation of functional steroid receptors and ligand-induced responses in telomerase-immortalized human endometrial epithelial cells
###end article-title 104
###begin article-title 105
Endocrine regulation of menstruation
###end article-title 105
###begin article-title 106
###xml 66 71 <span type="species:ncbi:9606">human</span>
Evidence for altered regulation of I kappa B alpha degradation in human colonic epithelial cells
###end article-title 106
###begin article-title 107
###xml 45 50 <span type="species:ncbi:9606">human</span>
Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation
###end article-title 107
###begin article-title 108
Prostaglandins and the initiation of blastocyst implantation and decidualization
###end article-title 108
###begin article-title 109
###xml 25 30 <span type="species:ncbi:9606">human</span>
The NF-kappaB pathway in human endometrium and first trimester decidua
###end article-title 109
###begin article-title 110
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members
###end article-title 110
###begin article-title 111
###xml 40 45 <span type="species:ncbi:9606">human</span>
Expression of nuclear factor kappa B in human endometrium; role in the control of interleukin 6 and leukaemia inhibitory factor production
###end article-title 111
###begin article-title 112
###xml 32 37 <span type="species:ncbi:9606">human</span>
Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle
###end article-title 112
###begin article-title 113
###xml 33 38 <span type="species:ncbi:9606">human</span>
Expression of cyclo-oxygenase in human endometrium during the implantation period
###end article-title 113
###begin article-title 114
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues
###end article-title 114
###begin article-title 115
###xml 75 80 <span type="species:ncbi:9606">human</span>
Expression, localization, and signaling of PGE(2) and EP2/EP4 receptors in human nonpregnant endometrium across the menstrual cycle
###end article-title 115
###begin article-title 116
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth
###end article-title 116
###begin article-title 117
###xml 23 28 <span type="species:ncbi:9606">human</span>
Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors
###end article-title 117
###begin article-title 118
Dating the endometrial biopsy
###end article-title 118
###begin article-title 119
###xml 51 56 <span type="species:ncbi:9606">human</span>
Expression of nuclear factor kappa B components in human endometrium
###end article-title 119
###begin article-title 120
###xml 31 36 <span type="species:ncbi:9606">human</span>
Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites
###end article-title 120
###begin article-title 121
Direct interaction between estrogen receptor alpha and NF-kappaB in the nucleus of living cells
###end article-title 121
###begin article-title 122
TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B
###end article-title 122
###begin article-title 123
###xml 172 177 <span type="species:ncbi:9606">human</span>
Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells
###end article-title 123
###begin article-title 124
###xml 26 30 <span type="species:ncbi:10090">mice</span>
Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist
###end article-title 124
###begin article-title 125
###xml 29 34 <span type="species:ncbi:9606">human</span>
The interleukin-1 system and human implantation
###end article-title 125
###begin article-title 126
###xml 96 101 <span type="species:ncbi:9606">human</span>
Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells
###end article-title 126
###begin article-title 127
Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation
###end article-title 127
###begin article-title 128
NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants
###end article-title 128
###begin article-title 129
Molecular complexity in establishing uterine receptivity and implantation
###end article-title 129
###begin article-title 130
Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment
###end article-title 130
###begin article-title 131
###xml 63 68 <span type="species:ncbi:9606">human</span>
Progesterone receptor subtype B is differentially regulated in human endometrial stroma
###end article-title 131
###begin article-title 132
Synergistic activation of the serotonin-1A receptor by nuclear factor-kappa B and estrogen
###end article-title 132

